Alps Advisors Inc Arcutis Biotherapeutics, Inc. Transaction History

Alps Advisors Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$10.23 - $17.14 $11,242 - $18,836	-1,099 Reduced 2.66%	40,244 $442,000
Q4 2022 Feb 14, 2023	BUY	$13.96 - $20.4 $119,078 - $174,012	8,530 Added 26.0%	41,343 $611,000
Q3 2022 Nov 14, 2022	BUY	$17.85 - $26.95 $41,304 - $62,362	2,314 Added 7.59%	32,813 $627,000
Q2 2022 Aug 11, 2022	SELL	$16.33 - $22.2 $347,567 - $472,504	-21,284 Reduced 41.1%	30,499 $650,000
Q1 2022 May 16, 2022	SELL	$14.38 - $22.79 $92,319 - $146,311	-6,420 Reduced 11.03%	51,783 $997,000
Q4 2021 Feb 09, 2022	SELL	$14.98 - $25.5 $50,557 - $86,062	-3,375 Reduced 5.48%	58,203 $1.21 Million
Q3 2021 Nov 15, 2021	SELL	$19.28 - $27.1 $87,646 - $123,196	-4,546 Reduced 6.87%	61,578 $1.47 Million
Q2 2021 Aug 11, 2021	SELL	$24.42 - $34.75 $598,045 - $851,027	-24,490 Reduced 27.03%	66,124 $1.81 Million
Q1 2021 May 07, 2021	BUY	$24.47 - $36.98 $528,282 - $798,361	21,589 Added 31.28%	90,614 $2.62 Million
Q4 2020 Feb 03, 2021	BUY	$17.82 - $31.73 $362,298 - $645,102	20,331 Added 41.75%	69,025 $1.94 Million
Q3 2020 Nov 04, 2020	SELL	$23.44 - $32.28 $78,734 - $108,428	-3,359 Reduced 6.45%	48,694 $1.43 Million
Q2 2020 Aug 05, 2020	BUY	$24.48 - $36.56 $1.27 Million - $1.9 Million	52,053 New	52,053 $1.57 Million

193

127M

5.43M

257K

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $616M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.